Stereotaxis Q2 2026 revenue $7.7M; robotic catheter revenue tops $1M, up 270% sequentially

Stereotaxis, Inc.

Q2 2026 revenue $7.7M; system revenue $1.5M (vs $3.0M year-ago), recurring revenue $6.2M (vs $5.8M year-ago).
Net loss widened to $4.5M from $3.8M year-ago; adjusted net loss $2.0M vs $1.3M; operating loss $4.6M.
Robotic catheter revenue surpassed $1M in the quarter, growing 270% sequentially; first US GenesisX purchase announced.
Cash $10.5M with no debt at June 30, 2026; expects recurring revenue ~$7M in Q3 and ~$8M in Q4 2026.
Completed Robocath acquisition; multiple Synchrony OR systems sold after April FDA clearance; cash flow profitability targeted 1H 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.